title: Immediate postoperative use of a topical agent to prevent intraocular pressure elevation after pars plana vitrectomy with gas tamponade.
abstract: OBJECTIVE
  To determine whether a single topical aqueous suppressant applied immediately after pars plana vitrectomy with long-acting gas tamponade prevents intraocular pressure (IOP) elevation.
  
  
  METHODS
  Fifty patients who met the inclusion criteria and underwent pars plana vitrectomy with long-acting gas tamponade were randomized to receive a combination of timolol maleate and dorzolamide hydrochloride, long-acting timolol alone, dorzolamide alone, or placebo at the conclusion of surgery. The IOP was checked by a portable, handheld tonometer (Tono-Pen) at the conclusion of surgery and at 5 hours, 1 day, and 1 week after surgery.
  
  
  RESULTS
  There were no significant differences in IOP among the groups at the conclusion of surgery. The IOP at 5 hours after surgery (27.0 vs 17.4 mm Hg; P<.001) and 1 day after surgery (26.1 vs 19.9 mm Hg; P =.01) showed a statistically significant difference between the placebo and timolol-dorzolamide groups. The timolol-dorzolamide group showed greater IOP control than either the timolol alone or the dorzolamide alone groups at 5 hours (P =.04 for both).
  
  
  CONCLUSIONS
  The use of a single topical aqueous suppressant (timolol-dorzolamide) given after pars plana vitrectomy with long-acting gas tamponade effectively prevents significant postoperative IOP elevation at 5 hours and 1 day after surgery.
authors.affiliation: Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, FL, USA.
authors.forename: Matthew S
authors.initials: MS
authors.lastname: Benz
authors.forename: Erika M
authors.initials: EM
authors.lastname: Escalona-Benz
authors.forename: Timothy G
authors.initials: TG
authors.lastname: Murray
authors.forename: Charles W G
authors.initials: CW
authors.lastname: Eifrig
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Yoder
authors.forename: Jeffrey K
authors.initials: JK
authors.lastname: Moore
authors.forename: Joyce C
authors.initials: JC
authors.lastname: Schiffman
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005466:Fluorocarbons; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D011184:Postoperative Period; D011446:Prospective Studies; D012163:Retinal Detachment / Q000601:surgery; D012167:Retinal Perforations / Q000601:surgery; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D013459:Sulfur Hexafluoride; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use; D013999:Timolol / Q000008:administration & dosage / Q000627:therapeutic use; D014821:Vitrectomy
chemical_list: D000959:Antihypertensive Agents; D005466:Fluorocarbons; D013449:Sulfonamides; D013876:Thiophenes; D013999:Timolol; C062765:dorzolamide; C042852:perflutren; D013459:Sulfur Hexafluoride